Therefore, more research on the use of heart failure medications and their impact on survival in the cardiac amyloidosis population is necessary, while considering dosing, subtyping of amyloidosis, and clinical disease stage and including SGLT2 inhibitors in a larger study population. Here, SLC5A2 is linked to heart failure.